Archive

This is my archive

Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer

Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen for Hepatitis B (“HBV”) ATLANTA, Dec. 01, 2020 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today… Read More